Effects of DOACs on Mouse Melanoma Metastasis and the Inhibitory Mechanism of Edoxaban, a Factor Xa-Specific DOAC [0.03%]
DOAC对小鼠黑色素瘤转移的影响及达比加群酯的特异性抑制机制研究
Keiichi Hiramoto,Taisei Watanabe,Masashi Imai et al.
Keiichi Hiramoto et al.
Introduction: Direct oral anticoagulants (DOACs) have been widely used in patients with thromboembolism. We previously reported that among DOACs, edoxaban (EDX), a factor Xa (FXa)-specific DOAC, most effectively inhibited...
Andreas Verstraete,Nicholas Cauwenberghs,Shayan Calhori et al.
Andreas Verstraete et al.
Background: Venous thromboembolism (VTE) is a significant contributor to global morbidity and mortality. Although management strategies and the distribution of risk factors have evolved, contemporary epidemiologic data ar...
Corrigendum: Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A [0.03%]
FVIII治疗重度HA成人及青少年患者的临床结局观察研究的勘误通知书
Pratima Chowdary,Liane Khoo,Michael Wang et al.
Pratima Chowdary et al.
[This corrects the article DOI: 10.1055/a-2621-9749.]. The Author(s). This is an open access article published by Thieme under the terms of the Creative ...
Platelet RNA-Seq Reveals Genes Associated with Carotid Intima-Media Thickness: A Cross-Sectional Study [0.03%]
基于血小板RNA测序的颈动脉内膜中层厚度相关的基因：横断面研究
Zhanfei Tan,Fan Guo,Jiaming Gao et al.
Zhanfei Tan et al.
Background: Although the association between platelet characteristics and the risk of developing atherosclerosis (AS) has been acknowledged, the specific role of platelets in AS development and progression remains unclear...
Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study [0.03%]
抗磷脂综合征患者反复血栓形成的危险因素-单中心队列研究
Natali Karandyszowska,Francesca Faustini,Hevgin Alagündüz et al.
Natali Karandyszowska et al.
Background: Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity. ...
Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY [0.03%]
新型口服抗凝药在门诊静脉血栓治疗中的应用：来自DRESDEN NOAC登记研究的患者数据
Luise Tittl,Christina Köhler,Sandra Marten et al.
Luise Tittl et al.
Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings. We extracted data from the prospective, noninterv...
Corrigendum: Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives [0.03%]
癌症相关血栓的管理：未满足的需求和未来展望（勘误）
Anna Falanga,Grégoire Le Gal,Marc Carrier et al.
Anna Falanga et al.
[This corrects the article DOI: 10.1055/s-0041-1736037.]. The Author(s). This is an open access article published by Thieme under the terms of the Creati...
von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report [0.03%]
两个患血管性血友病兄弟的抑制物产生现象：一例报告
Claudia Djambas Khayat,Anna Pavlova,Sylvia Werner et al.
Claudia Djambas Khayat et al.
The development of inhibitors to von Willebrand factor (VWF) is a rare but potentially serious complication of VWF replacement therapy in patients with von Willebrand disease (VWD). Patients who develop VWF inhibitors may become unresponsiv...
Patient's Awareness of Cancer-Associated Thrombosis: A Canadian Nationwide Survey [0.03%]
加拿大全国癌症相关血栓患者意识调查
Ana C Pizzarossa,Andrea Penaloza,Kristina Vrotniakaite-Bajerciene et al.
Ana C Pizzarossa et al.
Background: Approximately 20% of patients with cancer will have cancer-associated venous thromboembolism (CAT), which is associated with significant morbidity and mortality. Despite its clinical importance, CAT awareness ...
Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A [0.03%]
一项有关八因子治疗成人及青少年重症甲型血友病的临床疗效的前瞻性观察研究
Pratima Chowdary,Liane Khoo,Michael Wang et al.
Pratima Chowdary et al.
Objective: To assess real-world treatment patterns and outcomes in previously treated patients ≥12 years old with severe haemophilia A treated with marketed factor VIII (FVIII) replacement products. ...